Pigment Cell & Melanoma Research最新文献

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines. 粘膜和肢端黑色素瘤细胞系的生成技术。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-09-01 DOI: 10.1111/pcmr.70117

Ishani Banik, Sugandha Basu, Meng Wang, Austin J Escobar, Veronica Steri, Juan A Camara Serrano, Paul Phojanakong, Noel Cruz Pacheco, Katy K Tsai, Edwin A Alvarez, Adil Daud, Ivan H El-Sayed, Anastasia Samarkina, Joy Xu, Jamie D Aquino, Min Xiao, Meenhard Herlyn, Iwei Yeh

引用次数: 0

Staurosporine Drives Non-Canonical Melanocyte Maturation by Coupling β-Catenin Signaling to Actin-Dependent Dendrite Remodeling Staurosporine通过偶联β-Catenin信号和肌动蛋白依赖性树突重塑驱动非典型黑素细胞成熟

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-08-13 DOI: 10.1111/pcmr.70116

Kangning Xu, Lingli Yang, Sylvia Lai, Fei Yang, Yasutaka Kuroda, Daisuke Tsuruta, Ichiro Katayama

{"title":"Staurosporine Drives Non-Canonical Melanocyte Maturation by Coupling β-Catenin Signaling to Actin-Dependent Dendrite Remodeling","authors":"Kangning Xu, Lingli Yang, Sylvia Lai, Fei Yang, Yasutaka Kuroda, Daisuke Tsuruta, Ichiro Katayama","doi":"10.1111/pcmr.70116","DOIUrl":"https://doi.org/10.1111/pcmr.70116","url":null,"abstract":"Skin pigmentation relies on the coordinated regulation of melanin production and dendritic morphology to ensure effective pigment distribution. While staurosporine is widely used as a pro-apoptotic agent in malignant cells, its effects on normal human melanocytes remain poorly understood. Here, we investigated the effects of staurosporine on melanocyte biology and identified it as a potent inducer of non-canonical melanocyte maturation at sub-cytotoxic concentrations without stimulating melanocyte proliferation. In primary human melanocytes, staurosporine enhanced melanogenesis and promoted dendrite formation, elongation, and branching, resulting in acquisition of a mature melanocyte phenotype distinct from its apoptotic effects in melanoma cells. These phenotypic changes were accompanied by activation of β-catenin signaling together with coordinated remodeling of Rho family protein expression and the actin cytoskeleton. Topical application of staurosporine increased physiological pigmentation in guinea pig skin without detectable inflammation or melanocyte proliferation. Furthermore, staurosporine accelerated repigmentation in a rhododendrol-induced leukoderma model by promoting functional maturation of epidermal melanocytes and enhancing nuclear localization of β-catenin. Collectively, our findings identify staurosporine as a non-canonical regulator of melanocyte maturation and demonstrate that functional maturation, rather than proliferative expansion, is sufficient to enhance pigmentation under both physiological and depigmented conditions.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"39 5","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148753450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Melanoma and Hematologic Malignancies: Evidence From the NIH Precision Medicine Initiative 黑色素瘤和血液恶性肿瘤之间的关联：来自NIH精准医学倡议的证据

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-08-12 DOI: 10.1111/pcmr.70115

Mihir Kumar, Amritpal Kooner, Anchit Chauhan, Rawle A. Sekhon

引用次数: 0

CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice CD40激动剂治疗黑色素瘤：将临床前希望转化为临床实践。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-24 DOI: 10.1111/pcmr.70114

Xing Wei, YanDong Li, DeXuan Gao

{"title":"CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice","authors":"Xing Wei, YanDong Li, DeXuan Gao","doi":"10.1111/pcmr.70114","DOIUrl":"10.1111/pcmr.70114","url":null,"abstract":"Melanoma is an aggressive skin cancer that, once metastatic, accounts for a disproportionate share of skin-cancer mortality. Contemporary management includes surgical excision with sentinel-node assessment, adjuvant or neoadjuvant systemic therapy, radiotherapy in selected settings, targeted inhibition for BRAF/MEK-mutant disease, and intralesional modalities; nevertheless, many patients require effective systemic options. Immunotherapy has transformed outcomes by restoring antitumor T-cell activity. Within this paradigm, activation of CD40, a pivotal costimulatory receptor on antigen-presenting cells (APCs), has emerged as a means to reprogram tumor immunity in melanoma. Available agents span several classes, including agonist monoclonal antibodies, CD40L-based fusion proteins, and engineered bispecific or conditionally activatable formats. A principal mechanism is dendritic-cell licensing that enhances cross-priming of melanoma-specific CD8+ T cells. This review summarizes the latest evidence on CD40 agonist therapy in melanoma, moving from biological rationale to translational data. We summarize mechanistic underpinnings, delineate therapeutic classes and leading agents, and critically appraise findings from preclinical models and early-phase clinical studies, including signals of activity and salient safety considerations. Finally, we outline future perspectives for integrating CD40 agonists with established standards of care and for prioritizing biomarker-guided development to translate preclinical promise into durable clinical benefit.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"39 4","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Recessive oca2 Mutation Underlies Albinism in Xiphophorus Fish 隐性oca2突变是剑鱼白化病的基础。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-22 DOI: 10.1111/pcmr.70113

Yanting Xing, William Boswell, Jessica Parker, Kang Du, Manfred Schartl, Yuan Lu

引用次数: 0

Characterizing the Mutational Landscape of In-Transit Melanoma Metastases 描述运输中黑色素瘤转移的突变景观。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-14 DOI: 10.1111/pcmr.70112

Luisa Quesada Camacho, Mohamad El Moheb, Mackenzie M. Mayhew, Margaret G. Mercante, Emily G. Tocco, Nidhi Kuchimanchi, Susan J. Kim, Kaelyn C. Cummins, Lynn T. Dengel, Allan Tsung, Craig L. Slingluff Jr, Mohammad Fallahi-Sichani, Russell G. Witt

{"title":"Characterizing the Mutational Landscape of In-Transit Melanoma Metastases","authors":"Luisa Quesada Camacho, Mohamad El Moheb, Mackenzie M. Mayhew, Margaret G. Mercante, Emily G. Tocco, Nidhi Kuchimanchi, Susan J. Kim, Kaelyn C. Cummins, Lynn T. Dengel, Allan Tsung, Craig L. Slingluff Jr, Mohammad Fallahi-Sichani, Russell G. Witt","doi":"10.1111/pcmr.70112","DOIUrl":"10.1111/pcmr.70112","url":null,"abstract":"In-transit melanoma (ITM) is a unique presentation of metastatic cutaneous melanoma associated with therapeutic challenges. Despite its clinical importance, the molecular drivers of ITM remain poorly defined. We aimed to characterize the mutational landscape of ITM and identify genetic alterations distinguishing it from other melanoma metastases. Tumor samples from 528 patients in the MSK-IMPACT dataset, comprised of over 300 cancer-related genes, were analyzed. Samples were classified as primary, in-transit, regional lymph node, or distant metastases. Driver mutation frequencies were compared across groups, and mutual information (MI) and principal component analysis (PCA) were used to identify ITM-associated genes and mutation patterns. NRAS Q61 mutations were enriched in ITM compared with other melanoma sites, while NF1 mutations were less common. Exploratory MI, PCA, and pairwise analyses identified recurrent NRASMUT/wild-type gene patterns that may distinguish ITM from other melanoma samples. Genes retained in the wild-type state alongside NRASMUT were associated with PI3K/AKT/mTOR, TGF-β, and E2F-related pathways. Collectively, these findings suggest that ITM is enriched for NRAS Q61 mutations and may have a comparatively lower co-mutation burden, providing a basis for future studies of ITM biology and clinical behavior.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"39 4","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70112","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148443598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Evolutionary Patient Journey in Uveal Melanoma 葡萄膜黑色素瘤患者的进化之旅。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-11 DOI: 10.1111/pcmr.70111

Kevin O'Neill

{"title":"An Evolutionary Patient Journey in Uveal Melanoma","authors":"Kevin O'Neill","doi":"10.1111/pcmr.70111","DOIUrl":"10.1111/pcmr.70111","url":null,"abstract":"<div>\u0000 \u0000 Patients who receive a rare cancer diagnosis begin a diagnostic and treatment journey which is complicated by personal fear of the unknown and the reality of a scientific and clinical research community which may not have many insights, options, and definitive answers to enable long-term survival. Patients and families may initially struggle to find clinicians well-informed in the rare cancer and clinical trials of emerging therapies. Patient advocacy groups focused on specific rare cancers have established an important role and point of contact for connecting patients who share the same diagnosis, for sharing experience and perspective along the clinical journey. In this article, a patient diagnosed with uveal melanoma (UM) relates the elements of his unfolding clinical journey and the influence of a unique patient advocacy group impacting his care, decisions, personal advocacy for optimizing his own care, and quest for new and meaningful therapeutic opportunities. This journey is accompanied by a rapid evolution of prognostic analytical and clinical therapeutic research overlapping the same time frame. Key insights along the patient journey identify opportunities for clinicians to more closely observe and resolve acute and late sequelae which significantly impact quality of life after the initial diagnosis and treatment. In this article, a patient with a diagnosis of uveal melanoma recounts their diagnostic and treatment experience over 6 years. The author's insights on clinical interactions and miscues may help inform those involved in cancer research on revolutionary advances in prognostic genomics in a rare disease.\u0000 </div>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"39 4","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients 多基因面板检测对高危葡萄膜黑色素瘤患者的影响。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-07 DOI: 10.1111/pcmr.70108

Lindsey Byrne, Isabella Gray, Kaylee Ramsey, Joseph McElroy, Emma Schreiner, Jenna Wolfe, Olivia B. Taylor, Frederick Davidorf, Colleen M. Cebulla, Mohamed H. Abdel-Rahman

{"title":"Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients","authors":"Lindsey Byrne, Isabella Gray, Kaylee Ramsey, Joseph McElroy, Emma Schreiner, Jenna Wolfe, Olivia B. Taylor, Frederick Davidorf, Colleen M. Cebulla, Mohamed H. Abdel-Rahman","doi":"10.1111/pcmr.70108","DOIUrl":"10.1111/pcmr.70108","url":null,"abstract":"Germline genetic testing is increasingly incorporated into the care of patients with uveal melanoma, yet optimal testing strategies remain unclear. This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021 and 9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multigene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes (BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2). Among unrelated individuals, the positive rate was 13% (8/69). Excluding carrier genes, the rate was 10.1% (7/69). Eight patients would have been missed if only tested for BAP1 per American Society of Clinical Oncology (ASCO) 2024 recommendations. There was no association between tumor size, stage, and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, these findings support genetic counseling for multigene panel testing in high-risk uveal melanoma patients. Further studies of the impact of germline variants on UM disease outcome are warranted.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"39 4","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Copying the Risk: Rise of Phenocopies in CDKN2A Spanish Families 复制风险：CDKN2A西班牙家族表型的增加。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-07 DOI: 10.1111/pcmr.70091

Luna Amalia, Potrony Miriam, Badenas Celia, Podlipnik Sebastian, Carrera Cristina, Malvehy Josep, Puig Susana, Aguilera Paula

引用次数: 0

Histopathological Analysis Revealed Melanosome-Retaining Fibroblasts and Autophagy-Impaired Macrophages in Ashy Dermatosis 组织病理学分析显示灰色皮肤病中保留黑素体的成纤维细胞和自噬受损的巨噬细胞。

IF 3.5 3区医学

Pigment Cell & Melanoma Research Pub Date : 2026-07-06 DOI: 10.1111/pcmr.70110

Motoki Hada, Kazunori Yokoi, Daiki Murase, Hanako Koguchi-Yoshioka, Manabu Fujimoto, Atsushi Tanemura

{"title":"Histopathological Analysis Revealed Melanosome-Retaining Fibroblasts and Autophagy-Impaired Macrophages in Ashy Dermatosis","authors":"Motoki Hada, Kazunori Yokoi, Daiki Murase, Hanako Koguchi-Yoshioka, Manabu Fujimoto, Atsushi Tanemura","doi":"10.1111/pcmr.70110","DOIUrl":"10.1111/pcmr.70110","url":null,"abstract":"<div>\u0000 \u0000 Ashy dermatosis is a rare acquired dermal hyperpigmented disorder classified as a subtype of macular pigmentation of uncertain etiology. Recent studies have suggested that fibroblasts, in addition to macrophages known as melanophages, can phagocytose melanosomes under in vitro conditions. To clarify the cellular competition involved in dermal melanosome uptake, we examined 14 biopsy samples from patients with ashy dermatosis and performed histopathologic and immunohistochemical analyses. Autophagy-related markers involved in the autolysosomal degradation pathway were additionally evaluated in a subset of cases (n = 7) and compared with healthy controls. Our findings demonstrated that fibroblasts exhibited significantly greater melanosome uptake than macrophages (p = 0.0049). In the subset analysis, p62 accumulation was significantly increased in dermal macrophages from patients with ashy dermatosis compared with healthy controls (p = 0.0101), suggesting impaired autophagic degradation. These findings propose a novel pathogenic mechanism in ashy dermatosis, in which fibroblasts may contribute more substantially than macrophages to melanosome uptake while also exhibiting impaired autophagic degradation, thereby promoting persistent dermal hyperpigmentation.\u0000 </div>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"39 4","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0